Telehealth to Reach 1.8 Million Patients by 2017
In 2012 there was estimated to be 308,000 patients remotely monitored by their healthcare provider for congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), diabetes, hypertension and mental health conditions worldwide. The majority of these were post-acute patients who have been hospitalised and discharged. As healthcare providers seek to reduce readmission rates and track disease progression, telehealth is projected to reach 1.8 million patients worldwide by 2017, according to The World Market for Telehealth – An Analysis of Demand Dynamics – 2012, a new report from InMedica, part of IHS (NYSE: IHS).
In addition to post-acute patients, telehealth is also used to monitor ambulatory patients – those who have been diagnosed with a disease at an ambulatory care facility but have not been hospitalised. However, telehealth has a much larger penetration in post-acute care as compared to ambulatory care patients as the majority of patients are only considered for home monitoring following hospital discharge to prevent readmission. In the U.S., for example, 140,000 post-acute patients were estimated to have been monitored by telehealth in 2012, as compared to 80,000 ambulatory patients.
Figure 1. World Telehealth Patients (thousands) By Disease
“A major challenge for telehealth, is for it to reach the wider population of ambulatory care patients. However, the clinical and economic outcomes for telehealth are more established for post-acute care patients. Indeed, even for post-acute care patients, telehealth is usually prescribed only in the most severe cases, and where patients have been hospitalised more than once in a year,“ commented Theo Ahadome, senior analyst at InMedica.
CHF currently accounts for the majority of telehealth patients; in addition to being one of the largest cost-burdens for hospitalisation, the clinical outcomes of telehealth for CHF patients are most established. The number of telehealth patients with COPD is also projected to grow strongly as telehealth focus continues to expand to respiratory diseases. The successful results of the Whole System Demonstrator (WSD) program in the U.K. are serving as strong evidence-base for the benefits of telehealth for COPD patients. However, by 2017, Diabetes is forecast to account for the second largest share of telehealth patients, overtaking COPD. Home monitoring of glucose levels for diabetes patients is more established through personal glucose monitors. There is an increasing drive to integrate these monitors with telehealth systems, allowing care givers access to patient glucose data.
Over the next five years, InMedica identifies four main drivers of telehealth demand:
IHS Media Relations
About IHS Inc. (www.ihs.com)
IHS (NYSE: IHS) is the leading source of information, insight and analytics in critical areas that shape today’s business landscape. Businesses and governments in more than 165 countries around the globe rely on the comprehensive content, expert independent analysis and flexible delivery methods of IHS to make high-impact decisions and develop strategies with speed and confidence. IHS has been in business since 1959 and became a publicly traded company on the New York Stock Exchange in 2005. Headquartered in Englewood, Colorado, USA, IHS is committed to sustainable, profitable growth and employs more than 6,000 people in 31 countries around the world.
IHS is a registered trademark of IHS Inc. All other company and product names may be trademarks of their respective owners. Copyright © 2013 IHS Inc. All rights reserved.